Drug intelligence / Profile preview

Lidan Rongshi

Development stage: Unknown
Lead developer: Lianyungang Kanion
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Lidan Rongshi is a botanical drug candidate, specifically a Traditional Chinese Medicine (TCM) formulation, developed by Jiangsu Kanion Pharmaceutical Co., Ltd. for the treatment of chronic cholecystitis and the dissolution of gallstones (cholelithiasis). It is formulated as a soft capsule for oral administration. The drug is designed to exert choleretic effects, promoting bile secretion and improving gallbladder function. Clinical development in China has progressed to Phase 2 trials (e.g., CTR20181644), following initial Phase 1 safety and tolerability assessments (CTR20160405).

Brand names: Lidan Rongshi Soft Capsule
Other names: Lidan Rongshi Ruanjiaonang

Beyond the preview

Go deeper on Lidan Rongshi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lidan Rongshi.

Explore the full profile